---
pmid: '23541952'
title: Control of autophagic cell death by caspase-10 in multiple myeloma.
authors:
- Lamy L
- Ngo VN
- Emre NC
- Shaffer AL 3rd
- Yang Y
- Tian E
- Nair V
- Kruhlak MJ
- Zingone A
- Landgren O
- Staudt LM
journal: Cancer Cell
year: '2013'
full_text_available: false
pmcid: PMC4059832
doi: 10.1016/j.ccr.2013.02.017
---

# Control of autophagic cell death by caspase-10 in multiple myeloma.
**Authors:** Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM
**Journal:** Cancer Cell (2013)
**DOI:** [10.1016/j.ccr.2013.02.017](https://doi.org/10.1016/j.ccr.2013.02.017)
**PMC:** [PMC4059832](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059832/)

## Abstract

1. Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub
2013  Mar 28.

Control of autophagic cell death by caspase-10 in multiple myeloma.

Lamy L(1), Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, 
Zingone A, Landgren O, Staudt LM.

Author information:
(1)Metabolism Branch, Center for Cancer Research, National Cancer Institute, 
National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.

Comment in
    Cancer Cell. 2013 Apr 15;23(4):425-6. doi: 10.1016/j.ccr.2013.04.001.

We performed a loss-of-function RNA interference screen to define therapeutic 
targets in multiple myeloma, a genetically diverse plasma cell malignancy. 
Unexpectedly, we discovered that all myeloma lines require caspase-10 for 
survival irrespective of their genetic abnormalities. The transcription factor 
IRF4 induces both caspase-10 and its associated protein cFLIPL in myeloma, 
generating a protease that does not induce apoptosis but rather blocks an 
autophagy-dependent cell death pathway. Caspase-10 inhibits autophagy by 
cleaving the BCL2-interacting protein BCLAF1, itself a strong inducer of 
autophagy that acts by displacing beclin-1 from BCL2. While myeloma cells 
require a basal level of autophagy for survival, caspase-10 tempers this 
response to avoid cell death. Drugs that disrupt this vital balance may have 
therapeutic potential in myeloma.

Copyright Â© 2013 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2013.02.017
PMCID: PMC4059832
PMID: 23541952 [Indexed for MEDLINE]
